Acadia Pharmaceuticals | Ativo Circulante



Current Assets Alterar Data
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
ALKERMES USD 1.42B 167.74M 2024-12
Alnylam Pharmaceuticals USD 3.3B 60.14M 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Corcept Therapeutics USD 471.6M 4.62M 2024-12
Cytokinetics USD 1.11B 89.34M 2024-12
Eisai JPY 761.1B 79.19B 2024-12
Eli Lilly USD 32.74B 1.32B 2024-12
Incyte USD 3.24B 430.32M 2024-12
J&J USD 55.89B 2.64B 2024-12
Moderna USD 8.1B 1.57B 2024-12
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Pfizer USD 50.36B 7.14B 2024-12
Prothena USD 485.41M 49.57M 2024-12
PTC Therapeutics USD 1.37B 83.98M 2024-12
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Acadia Pharmaceuticals Ativo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Apr 2025.